Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study

First‐line platinum‐based therapy for advanced squamous cell carcinomas of the anal canal (SCCA) implies a risk of substantial side effects, and data on second‐line treatment options are limited. Paclitaxel and Capecitabine are a well‐known regimen with a moderate toxicity profile, but its efficacy has not been evaluated.

[1]  K. Bénézery,et al.  Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal , 2019, Cancer medicine.

[2]  K. Canfell,et al.  Anal cancer in high-income countries: Increasing burden of disease , 2018, PloS one.

[3]  K. Jensen,et al.  A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine , 2018, Front. Oncol..

[4]  F. Sclafani,et al.  Systemic Therapies for Advanced Squamous Cell Anal Cancer , 2018, Current Oncology Reports.

[5]  V. Gorbounova,et al.  Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma , 2017, Cancer Chemotherapy and Pharmacology.

[6]  D. Cunningham,et al.  Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. , 2017, The oncologist.

[7]  A. Jemal,et al.  International trends in anal cancer incidence rates. , 2016, International journal of epidemiology.

[8]  P. Boland,et al.  Systemic therapy for advanced anorectal squamous cell carcinomas: A single institutional experience. , 2016 .

[9]  S. Barni,et al.  Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies , 2015, Acta oncologica.

[10]  J. Vauthey,et al.  The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal , 2014, Oncotarget.

[11]  R. Jang,et al.  Simple prognostic model for patients with advanced cancer based on performance status. , 2014, Journal of oncology practice.

[12]  D. Shibata,et al.  Carboplatin and Paclitaxel Treatment Is Effective in Advanced Anal Cancer , 2014, Oncology.

[13]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[14]  D. Sebag‐Montefiore,et al.  Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[15]  M. Fakih,et al.  Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. , 2011, Anticancer research.

[16]  D. Gupta,et al.  Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature , 2010, Nutrition journal.

[17]  Y. Tanaka,et al.  Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  K. Adachi,et al.  Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. , 1996, British Journal of Cancer.

[19]  G. Tanum.  Treatment of relapsing anal carcinoma. , 1993, Acta oncologica.